Document:

Exhibit 10.2

    

     

      

    
      	 	
              CONFIDENTIAL

            
	
               

              Certain confidential information contained in this document, marked by [**], has been omitted because ADC 

              Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive 

              harm to ADC Therapeutics SA (ADCT) if publicly disclosed.

               

            

    

    
       

        

      Amendment# 1

      

      

      to the Second Amended and Restated License Agreement dated May 9, 2016

      

      

      This Amendment# 1 (“Amendment

        #1”) dated 19 September 2018 (“Amendment Effective Date”) is made by and between ADC Products (UK) Ltd., with registered address at registered office is at 4th Floor, Reading Bridge House, George Street, Reading, Berkshire RG l 8LS, United Kingdom
        (“ADCP”), ADC Therapeutics SA, with registered address at Route de la Corniche 3B, 1066 Epalinges,

        Switzerland (“ADCT”), and Medimmune Ltd., with registered office at Milstein
        Building, Granta Park, Cambridge CB21 6GH (“Medlmmune”), each hereinafter individually referred to as “Party”

        and jointly as “Parties”.

      

      

      WHEREAS, the Parties executed a Second Amended and Restated License Agreement on May
        9, 2016 (“License Agreement”), amending and restating the First Amended and Restated License Agreement dated October 14, 2013 which amended the Original License Agreement dated September 1, 2011;

      

      

      WHEREAS, the Parties wish to amend the License Agreement according to the terms and conditions of this Amendment #1;

      

      

      NOW, THEREFORE, for good and valuable consideration, the receipt and sufficient of
        which is hereby acknowledged, the Parties agree as follows

      

      

      
        
          	1.	
                  The Parties agree to cancel, delete and replace Section 2.3.3. of the License Agreement with the following new Section 2.3.3:

                

        

      

      

      

      “2.3.3 Replacement of Licensed Targets. ADCT may, at its
        discretion at any time until and including [**], replace the Approved Target of any Commercial License with another Approved Target (selected in accordance with Section 2.3.1)
        provided that in aggregate the number of replacements for all (a) ADC Commercial Licenses shall not exceed eleven
        (11), and (b) Non-ADC Commercial Licenses shall not exceed ten (10).”

      

      

      
        
          	2.	
                  Unless they are defined in this Amendment #1, all terms used with a capital and not defined herein shall have the meaning set forth in the License Agreement.

                

        

      

      

      

      
        
          	3.	
                  All other terms and conditions of the License Agreement shall remain in full force and effect. In the event of any conflict between this Amendment #1 and the License Agreement, this
                    Amendment #1 shall prevail.

                

        

      

      

      

      
        
          	4.	
                  This Amendment #1 shall enter into force on the Amendment Effective Date set forth above and shall be governed by English law.

                

        

      

      

      

      IN WITNESS WHEREOF, the Parties have executed this Amendment #l on the Amendment Effective Date.

      

      

      [Signature page follows]

      
        Page 1 of 2

        
          

      

      
       CONFIDENTIAL

       

      

      	
              ADC PRODUCTS (UK) LTD.

            	 	
              ADC THERAPEUTICS SA

            
	 	 	 	 	 
	 	 	 	 	 
	
              By:

            	
              /s/ Michael Forer

            	 	
              By:

            	
              /s/ Chris Martin

            
	
              Name:

            	
              Michael Forer

            	 	
              Name:

            	
              Chris Martin

            
	
              Title:

            	
              Director

            	 	
              Title:

            	
              CEO

            

      

      

      	
              MEDIMMUNE LTD.

            
	 	 	 	 	 
	 	 	 	 	 
	
              By:

            	
              /s/ C S Winter

            	 	 	 
	
              Name:

            	
              Christopher S. Winter

            	 	 	 
	
              Title:

            	
              Authorised Signatory

            	 	 	 

      

      

      

      

    

  

  Page 2 of 2

  

    Certain confidential information contained in this document, marked by [**], has been omitted because ADC 

    Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause 

    competitive harm to ADC Therapeutics SA (ADCT) if publicly disclosed.Exhibit 10.12

     

  	
          womblebonddickinson.com

        	 

   

  1 July 2019

   

  Deed Of Variation

  Relating To

  Lease of Suite 5, First Floor, The Queen Mary Bioenterprises Innovation

  Centre, 42 New Road, London

   

  Queen Mary Bioenterprises Limited (1) and

  ADC Therapeutics (UK) Limited (2)

   

  Womble Bond Dickinson (UK) LLP

  Tel +44(0)345 415 0000

  www.womblebonddickinson.com

   

  
    
      
 

  

  CONTENTS

   

  	Clause	Page
	 	 	 
	1.	INTERPRETATION	1
	2.	VARIATIONS TO THE LEASE	2
	3.	TENANT’S COVENANT	2
	4.	ENDORSEMENT	2
	5.	GOVERNING LAW	2
	6.	JURISDICTION	2
	7.	THIRD PARTY RIGHTS	2
	SCHEDULE 1	3
	 	Variations to the Lease	3

   

  
    
      
 

  

  
  PARTIES 

   

  		(1)	Queen Mary Bioenterprises Limited incorporated and registered in England and Wales with company number 04324033 whose registered office is at Queen Mary University of
          London, 327 Mile End Road, London, E1 4NS (Landlord).

   

  		(2)	ADC Therapeutics (UK) Limited incorporated and registered in England and Wales with company number 09353055 whose registered office is at 4th Floor, Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS (Tenant).

   

  BACKGROUND

   

  		(A)	This deed is supplemental and collateral to the Lease.

   

  		(B)	The Landlord and the Tenant have agreed to vary the Lease on the terms set out in this deed. 

   

  		(C)	The Landlord is entitled to the immediate reversion to the Lease.

   

  		(D)	The residue of the term granted by the Lease is vested in the Tenant.

   

  AGREED TERMS 

   

  		1.	INTERPRETATION 

   

  The following definitions and rules of interpretation apply in this deed.

   

  		1.1	Definitions:

   

  	 	Lease	a lease of the Property dated 14 September 2017 and made between (1) Queen Mary Bioenterprises
          Limited and (2) ADC Therapeutics (UK) Limited.
	 	 	 
	 	Property	Suite 5, First Floor of the Queen Mary Bioenterprises Innovation Centre as more particularly described in and demised by the Lease.

   

  		1.2	References to the Landlord include a reference to the person entitled for the time being to the immediate reversion to the Lease. References to the Tenant include a reference
          to its respective successors in title and assigns.

   

  		1.3	A reference to the Lease includes any deed, licence, consent, approval or other instrument supplemental to it.

   

  		1.4	A reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time.

   

  		1.5	A reference to a statute or statutory provision shall include all subordinate legislation made from time to time under that statute or statutory provision.

   

  		1.6	A person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality).

   

  		1.7	The expression tenant covenant has the meaning given to it by the Landlord and Tenant (Covenants) Act 1995.

   

  		1.8	Unless the context otherwise requires, words in the singular shall include the plural and in the plural shall include the singular.

   

  
    1

    
      
 

  

  		1.9	Unless the context otherwise requires, a reference to the Property is to the whole and any part of it.

   

  		1.10	Except where a contrary intention appears, references to clauses and Schedules are to the clauses and Schedules of this deed and references to paragraphs are to paragraphs of
          the relevant Schedule.

   

  		1.11	Clause, Schedule and paragraph headings shall not affect the interpretation of this deed.

   

  		1.12	Except to the extent that they are inconsistent with the definitions and interpretations in Clause 1 of this deed, the definitions and interpretations in clause 1 of the
          Lease shall apply to this deed.

   

  		2.	VARIATIONS TO THE LEASE 

   

  		2.1	Variations made

   

  		 	From and including the date of this deed, the Lease shall be read and construed as varied by the provisions set out in the Schedule.

   

  		2.2	Lease remains in force

   

  		 	The Lease shall remain fully effective as varied by this deed and the terms of the Lease shall have effect as though the provisions contained in this deed had been originally
          contained in the Lease.

   

  		3.	TENANT’S COVENANT

   

  The Tenant covenants to observe and perform the tenant’s covenants in the Lease as varied by this deed.

   

  		4.	ENDORSEMENT

   

  Promptly following completion of this deed both the Landlord and the Tenant shall each endorse a memorandum of variation upon the Lease and its counterpart
    in the following terms:

   

  “This Lease has been varied by a Deed of Variation dated [                    ] 2019 and made between (1) Queen Mary Bioenterprises Limited and (2) ADC
    Therapeutics (UK) Limited.

   

  		5.	GOVERNING LAW

   

  This deed and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims)
    shall be governed by and construed in accordance with the law of England and Wales.

   

  		6.	JURISDICTION 

   

  Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of or in
    connection with this deed or its subject matter or formation (including non-contractual disputes or claims).

   

  		7.	THIRD PARTY RIGHTS 

   

  A person who is not a party to this deed shall not have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this deed.
    This does not affect any right or remedy of a third party which exists or is available apart from that Act.

   

  This Deed has been entered into on the date stated at the beginning of it. 

  
    2

    
      
 

  

  SCHEDULE 1

   

  Variations to the Lease

   

  REPLACEMENT OF EXISTING DEFINITIONS

   

  The definition of “Break Date” shall be deleted and replaced with the following:-

   

  “Break Date” 1 July 2020 and 1 January 2022

  

  

  
    3

    
      
 

  

  
    	
            Executed as a deed by Queen Mary Bioenterprises

          	 
	
            Limited acting by a director and its secretary

          	
            Director  /s/ [Illegible]

          
	 	
            

            

          
	 	
            Director/Secretary  /s/ R. Richmond

          

  

  

  

  
    4

    
      
 

  

  
  
    	
            Executed as a deed by ADC Therapeutics (UK)

          	 
	
            Limited acting by a director and its secretary

          	
            Director  /s/ Michael Forer

          
	 	
            

            

          
	 	
            Director/Secretary  

            

          

  

  

  

  5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]